

A4
cont'd

(1) a single-chain multi-functional polypeptide [of any one of claims 1 to 16,]
comprising:

- (a) a first domain comprising a binding-site of an immunoglobulin chain or an antibody specifically recognizing the CD 19 antigen; and
- (b) a second domain comprising a binding site of an immunoglobulin chain or an antibody specifically recognizing the human CD3 antigen;

(2) the polynucleotide of claim 17; or

(3) the vector [of claim 18] comprising said polynucleotide [into a human affected by said pathological condition].

Kindly add the following claims:


- A5
- 32. The method of claim 27, wherein said CD19 positive cells are B-cells.
33. The method of claim 30, wherein said B-cell malignancy is non-Hodgkin lymphoma.
34. The method of claim 30, wherein the polynucleotide or vector comprising said polynucleotide comprises a composition suitable for gene therapy administration.--

REMARKS

Upon entry of this amendment, claims 1-23 and 27-34 will be pending. The claims have been amended to delete improper multiple dependencies and phrases that do not conform with U.S. patent practice. The claims are fully supported by the specification and original claims. Examination and allowance of these claims is earnestly requested.

Respectfully submitted,

October 20, 2000
Date


Stephen A. Bent
Reg. No. 29,768

FOLEY & LARDNER
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Phone: (202) 672-5300
Fax: (202) 672-5399

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY DEFICIENCY OR CREDIT ANY OVERPAYMENT TO DEPOSIT ACCOUNT NO. 19-0741.